Evaluation of the Safety and Efficacy of Recombinant Factor IX (nonacog Alfa) in Minimally Treated and Previously Treated Chinese Patients with Haemophilia B

R Yang,Y Zhao,X Wang,J Sun,J Jin,D Wu,R Charnigo,A O'Brien,Z Zhong,P Rendo
DOI: https://doi.org/10.1111/j.1365-2516.2012.02907.x
2012-01-01
Abstract:R. YANG,* Y . ZHAO, † X. WANG,‡ J . SUN,§ J . J IN , ¶ D. WU,** R . CHARNIGO,† † A. O ’BRIEN,†† Z. ZHONG‡‡ and P . RENDO†† *Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin; †Peking Union Medical College Hospital, Beijing; ‡Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai; §Nanfang Hospital, Southern Medical University, Guangzhou; ¶The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou; **The First Affiliated Hospital of Soochow University, Suzhou, China; ††Pfizer Inc, Collegeville, PA USA; and ‡‡Pfizer Inc, Beijing, China
What problem does this paper attempt to address?